🇺🇸·May 29CDMO
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
Publisher
E
Emergent BioSolutions
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Emergent BioSolutions
- Region
- USA
- Scope
- CDMO
- Published
- May 29, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on investors.emergentbiosolutions.com
Leave the platform to read the original full article on the publisher site.
Source: Emergent BioSolutions
Scope: CDMO
Related coverage
More related coverage
American Society of Nephrology·20h ago
New nephSAP Issue: Electrolytes and Acid-Base Disorders
University of Freiburg·20h ago
EPICUR Seed Funding 2026 – submit your project ideas now
Erasmus University Rotterdam·20h ago
Tâm Ngô appointed as endowed professor of Historical Anthropology of War Legacies
University of Freiburg·20h ago